Zobrazeno 1 - 10
of 65
pro vyhledávání: '"F Di Perna"'
Autor:
S Coppolino, F Di Perna
Publikováno v:
Section 6: Education and Research.
Background Repaglinide is an oral hypoglycemic drug especially useful for the treatment of type 2 diabetes. This molecule has poor aqueous solubility, which is the rate-limiting step for absorption of the drug. Solubility can be increased by forming
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4cec63caddffc9ef9d153a16c558830
https://doi.org/10.1136/ejhpharm-2019-eahpconf.614
https://doi.org/10.1136/ejhpharm-2019-eahpconf.614
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M D'Amato, Claudio Terzano, C. Califano, Maria Gabriella Matera, F. Di Perna, Gennaro D'Amato, Serafino A. Marsico, Mario Cazzola
Publikováno v:
Respiratory Medicine. 96:790-795
Worsening of underlying bronchospasm may be associated with acute exacerbations of chronic obstructive pulmonary disease (COPD). As airway obstruction becomes more severe, the therapeutic option is to add salbutamol, but not salmeterol, as needed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b6cdcd1f22c61a0503bafa8c10f68f7
https://doi.org/10.1053/rmed.2002.1353
https://doi.org/10.1053/rmed.2002.1353
Publikováno v:
Respiratory Medicine. 95(11):917-921
Worsening of underlying bronchospasm may be associated with acute exacerbations of chronic obstructive pulmonary disease (COPD). As airway obstruction becomes more severe, the therapeutic option is to add a short-acting inhaled beta2-agonist as neede
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b1e1d78b590e33e7b27b093370b286
Autor:
C. Regorda, F. Di Perna, Pierachille Santus, F. Di Marco, Stefano Centanni, B. Boveri, Mario Cazzola, Paolo Carlucci
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 14:41-45
We studied 16 patients with stable COPD in a double blind, double dummy, placebo-controlled, within patient study to see if formoterol could be used as a rescue drug. We compared the of onset of bronchodilation obtained with formoterol 12 microg (met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8707dbd9de3796dcd60f1943d60139d1
https://doi.org/10.1006/pupt.2000.0267
https://doi.org/10.1006/pupt.2000.0267
Autor:
Claudio F. Donner, C. Califano, Gennaro D'Amato, Maria D'Amato, Mario Cazzola, Stefano Centanni, F. Di Perna
Publikováno v:
Scopus-Elsevier
BACKGROUND An earlier study documented that, in patients with chronic obstructive pulmonary disease (COPD), addition of ipratropium bromide at the clinically recommended dose (40 μg) does not produce any further bronchodilation than that achieved wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49d4f7849641c2734fb6bc59489370bb
https://doi.org/10.1136/thx.54.12.1083
https://doi.org/10.1136/thx.54.12.1083
Autor:
A. Vinciguerra, C. Califano, F. Calderaro, F. Di Perna, Antonello Salzillo, Stefano Centanni, M. Cazzola
Publikováno v:
Journal of Chemotherapy. 11:119-125
We compared the clinical and microbiological efficacy of dirithromycin with that of azithromycin in outpatients with acute bacterial exacerbations of chronic bronchitis who could be graded into stage III according to Ball's system of stratification.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78e8608c900ce1e7590f0edb7c61f699
https://doi.org/10.1179/joc.1999.11.2.119
https://doi.org/10.1179/joc.1999.11.2.119
Publikováno v:
Journal of Chemotherapy. 9:279-284
Since dirithromycin persists at high concentrations in the lung for at least 3 days following the last dose of a 5-day course, we evaluated the clinical efficacy and tolerance of a 5-day course of dirithromycin in 20 patients with acute exacerbation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6d6776e34c1d82b216d0a08638dd1bc
https://doi.org/10.1179/joc.1997.9.4.279
https://doi.org/10.1179/joc.1997.9.4.279
Autor:
F. Calderaro, A. Vinciguerra, Francesca Rossi, M. Caputi, Mario Cazzola, F. Di Perna, Maria Gabriella Matera
Publikováno v:
Pulmonary Pharmacology. 8:267-271
Bronchodilator efficacy of salbutamol (200 micrograms), salmeterol (50 micrograms) and ipratropium bromide (40 micrograms) aerosols has been compared in 16 patients with stable chronic obstructive pulmonary disease (COPD) using a double-blind placebo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f47854da44d19905629ac5dfc8d1ea4
https://doi.org/10.1006/pulp.1995.1036
https://doi.org/10.1006/pulp.1995.1036
Autor:
F. Di Perna, Mario Cazzola, C. Califano, Maria Gabriella Matera, Gennaro Mazzarella, Maria D'Amato
Publikováno v:
Scopus-Elsevier
We examined the influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in patients with partially reversible stable COPD. Twenty outpatients inhaled one or two puffs of formoterol (12 microg puff(-1)),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea54a6ae1fc59cc90995176a1c7c3309